Reston, VA — A new imaging agent, Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the September issue of The Journal of Nuclear Medicine. By providing whole-body quantification of HER2 expression,…Read More
Wholebody PETCT predicts response to HER2targeted therapy in metastatic
